Denali Sells PRV for $195M
Analysis based on 6 articles · First reported Jun 18, 2026 · Last updated Jun 18, 2026
The sale of the Priority Review Voucher by Denali Therapeutics Inc. for $195 million is expected to positively impact the company's stock price due to increased financial flexibility. This capital infusion will enable Denali Therapeutics Inc. to accelerate its clinical pipeline, potentially leading to future drug developments and increased market value in the biotechnology sector.
Denali Therapeutics Inc. announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million. The United States — Food and Drug Administration awarded this PRV to Denali Therapeutics Inc. after the accelerated approval of AVLAYAH, an enzyme replacement therapy for Hunter syndrome, in March 2026. AVLAYAH is notable as the first FDA-approved biologic designed to cross the blood-brain barrier. Alexander Schuth, Chief Operating and Financial Officer of Denali Therapeutics Inc., stated that monetizing the PRV will enhance the company's financial flexibility and fund the advancement of its extensive clinical pipeline, which includes programs for lysosomal storage disorders and neurodegenerative diseases. The transaction is subject to customary closing conditions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard